Sebastian Hollizeck
Overview
Explore the profile of Sebastian Hollizeck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
829
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hollizeck S, Wang N, Wong S, Litchfield C, Guinto J, Ftouni S, et al.
Nat Commun
. 2024 Nov;
15(1):9876.
PMID: 39543119
The use of circulating tumour DNA (ctDNA) to profile mutational signatures represents a non-invasive opportunity for understanding cancer mutational processes. Here we present MisMatchFinder, a liquid biopsy approach for mutational...
2.
Lunke S, Bouffler S, Downie L, Caruana J, Amor D, Archibald A, et al.
BMJ Open
. 2024 Apr;
14(4):e081426.
PMID: 38569677
Introduction: Newborn bloodspot screening (NBS) is a highly successful public health programme that uses biochemical and other assays to screen for severe but treatable childhood-onset conditions. Introducing genomic sequencing into...
3.
Ghalandary M, Li Y, Frohlich T, Magg T, Liu Y, Rohlfs M, et al.
Sci Rep
. 2022 Mar;
12(1):3906.
PMID: 35273242
NOD2 polymorphisms may affect sensing of the bacterial muramyl dipeptide (MDP) and trigger perturbed inflammatory responses. Genetic screening of a patient with immunodeficiency and enteropathy revealed a rare homozygous missense...
4.
Fennell K, Vassiliadis D, Lam E, Martelotto L, Balic J, Hollizeck S, et al.
Nature
. 2021 Dec;
601(7891):125-131.
PMID: 34880496
All cancers emerge after a period of clonal selection and subsequent clonal expansion. Although the evolutionary principles imparted by genetic intratumour heterogeneity are becoming increasingly clear, little is known about...
5.
Lyszkiewicz M, Zietara N, Frey L, Pannicke U, Stern M, Liu Y, et al.
Nat Commun
. 2020 Apr;
11(1):1963.
PMID: 32312977
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
6.
Lyszkiewicz M, Zietara N, Frey L, Pannicke U, Stern M, Liu Y, et al.
Nat Commun
. 2020 Feb;
11(1):1031.
PMID: 32098969
Clathrin-mediated endocytosis (CME) is critical for internalisation of molecules across cell membranes. The FCH domain only 1 (FCHO1) protein is key molecule involved in the early stages of CME formation....
7.
Khoshnevisan R, Anderson M, Babcock S, Anderson S, Illig D, Marquardt B, et al.
Inflamm Bowel Dis
. 2020 Feb;
26(8):1166-1176.
PMID: 32064493
Background: Genetic defects of pediatric-onset inflammatory bowel disease (IBD) provide critical insights into molecular factors controlling intestinal homeostasis. NOX1 has been recently recognized as a major source of reactive oxygen...
8.
Prenzel F, Harfst J, Schwerk N, Ahrens F, Rietschel E, Schmitt-Grohe S, et al.
Pediatr Pulmonol
. 2020 Feb;
55(4):909-917.
PMID: 32040879
Objectives: Pediatric lymphocytic interstitial pneumonia (LIP) and follicular bronchiolitis (FB) are poorly characterized lymphoproliferative disorders. We present and quantify demographics, radiological and histopathologic patterns, treatments and their responses, and outcomes...
9.
Solomon B, Tan L, Lin J, Wong S, Hollizeck S, Ebata K, et al.
J Thorac Oncol
. 2020 Jan;
15(4):541-549.
PMID: 31988000
Introduction: Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC...
10.
Burr M, Sparbier C, Chan K, Chan Y, Kersbergen A, Lam E, et al.
Cancer Cell
. 2019 Oct;
36(4):385-401.e8.
PMID: 31564637
Loss of MHC class I (MHC-I) antigen presentation in cancer cells can elicit immunotherapy resistance. A genome-wide CRISPR/Cas9 screen identified an evolutionarily conserved function of polycomb repressive complex 2 (PRC2)...